Spots Global Cancer Trial Database for kit
Every month we try and update this database with for kit cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer | NCT02219711 | Advanced Cancer | MGCD516 | 18 Years - | Mirati Therapeutics Inc. | |
| A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies | NCT02571036 | Gastrointestina... Advanced System... Advanced Cancer... | DCC-2618 DCC-2618 | 18 Years - | Deciphera Pharmaceuticals LLC | |
| A Drug-drug Interaction Study of Avapritinib and Midazolam | NCT04908176 | Gastrointestina... GIST Non-resectable ... Recurrent or Un... | Avapritinib midazolam | 18 Years - | Blueprint Medicines Corporation | |
| Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST) | NCT00116935 | Sarcoma | imatinib mesyla... imatinib imatinib | 18 Years - | Scandinavian Sarcoma Group | |
| Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation | NCT03560908 | Relapsed AML T(8;21) C-KIT Mutation | Dasatinib | - | Institute of Hematology & Blood Diseases Hospital, China | |
| CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors | NCT02401815 | Gastrointestina... | PLX9486 Pexidartinib Sunitinib | 18 Years - | Cogent Biosciences, Inc. | |
| Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation | NCT03560908 | Relapsed AML T(8;21) C-KIT Mutation | Dasatinib | - | Institute of Hematology & Blood Diseases Hospital, China | |
| Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation | NCT03560908 | Relapsed AML T(8;21) C-KIT Mutation | Dasatinib | - | Institute of Hematology & Blood Diseases Hospital, China | |
| (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors | NCT05208047 | Advanced Gastro... Metastatic Canc... | CGT9486 plus su... CGT9486 Sunitinib Sunitinib | 18 Years - | Cogent Biosciences, Inc. | |
| Imatinib in Patients With Desmoid Tumor and Chondrosarcoma | NCT00928525 | Advanced Desmoi... Advanced Chondr... | Imatinib Mesyla... | 18 Years - 80 Years | Italian Sarcoma Group | |
| Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST) | NCT00116935 | Sarcoma | imatinib mesyla... imatinib imatinib | 18 Years - | Scandinavian Sarcoma Group | |
| A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies | NCT02571036 | Gastrointestina... Advanced System... Advanced Cancer... | DCC-2618 DCC-2618 | 18 Years - | Deciphera Pharmaceuticals LLC | |
| Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma | NCT04546074 | Melanoma | Pembrolizumab a... Pembrolizumab a... | 20 Years - | Keio University | |
| Imatinib in Patients With Desmoid Tumor and Chondrosarcoma | NCT00928525 | Advanced Desmoi... Advanced Chondr... | Imatinib Mesyla... | 18 Years - 80 Years | Italian Sarcoma Group |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
